References
- Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169(1-2):123–131.
- Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario. Can Am J Epidemiol 1999;150: 245–254.
- Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1993;21: 333–339.
- Glode LM, Robinson J, Gould SF. Protection from cyclo-phosphamide-induced testicular damage with an analogue of gonadotropin releasing hormone. Lancet 1981;1:1132–1134.
- Champman RM, Sutcliffe S. The effects of chemotherapy and radiotherapy on fertility and their prevention. Recent Adv Clin Oncol 1986;2:239–251.
- Krepart GV, Lotocki RJ. Chemotherapy during pregnancy. In: Allen HH, Nisker JA, editors. Cancer in pregnancy, therapeutic guidelines. Mount Kisco, NY: Futura Publishing; 1986. p 69–88.
- Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosph-amide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995;:86–92.
- Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemiotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 1999;6:229–239.
- Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemio-therapy. Hum Reprod 1996;11:1620–1626.
- Blumenfeld Z, Avivi I, Ritter M, Shariki K, Haim N. Inhibin-A concentration in sera of young women durino following chemotherapy for lymphoma correlation with ovarian toxicity. Presented at the 44th Annual Meeting of the Society for Gynecologic Investigation San Diego, CA, March 20–22, 1997, Am J Reprod Immumol 1998;39: 33–40.
- Beerendonk CC, Braat DD. Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev 2005;8:166–175.
- Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet 5, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19:159–162.
- Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997;29:199–206.
- Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe M. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002;13:138–147.
- Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol 2001;81:391–397.
- Yuce MA, Balkanli Kaplan P, Gucer F, Doganay L, Altaner S, Ganda T, et al. Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: A dose-dependent relationship? Eur J Gynaecol Oncol 2004;25(5):628–631.
- Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005; 11(1):69–89.
- Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transpl 2001;28(1):67–75.
- Wolff EF, Taylor HS. Value of the day 3 follicle-stimulating hormone measurement. Fertil Steril 2004;81(6):1486–1488.
- Coussieu C. Les inhibines dans l'hypofertilité féminine: Leur apport pour la pratique inhibins in woman's hypofertility: Practical interest. Gynécol Obstét Fertil 2004;32:760–766.
- Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 2005;45(1):20–24.
- Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: A meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005;83(2):291–330.